128 related articles for article (PubMed ID: 8513840)
1. Are systemic levels of non steroidal anti inflammatory drugs relevant to acute upper gastrointestinal haemorrhage?
Wynne HA; Rawlins MD
Eur J Clin Pharmacol; 1993; 44(4):309-13. PubMed ID: 8513840
[TBL] [Abstract][Full Text] [Related]
2. Are altered pharmacokinetics of non-steroidal anti-inflammatory drugs (NSAIDs) a risk factor for gastrointestinal bleeding?
Wynne HA; Long A; Nicholson E; Ward A; Keir D
Br J Clin Pharmacol; 1998 Apr; 45(4):405-8. PubMed ID: 9578191
[TBL] [Abstract][Full Text] [Related]
3. Piroxicam and gastrointestinal bleeding.
Giercksky KE
Am J Med; 1986 Nov; 81(5B):2-5. PubMed ID: 3491541
[TBL] [Abstract][Full Text] [Related]
4. Impact of preexisting health conditions on the outcome of an adverse drug reaction alerting program: gastrointestinal disorders before piroxicam and sulindac therapy.
Rawson NS
Ann Pharmacother; 1995; 29(7-8):676-80. PubMed ID: 8520079
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal blood loss in arthritic patients receiving chronic dosing with etodolac and piroxicam.
Jallad NS; Sanda M; Salom IL; Perdomo CS; Garg DC; Mullane JF; Weidler DJ
Am J Med Sci; 1986 Nov; 292(5):272-6. PubMed ID: 2946224
[TBL] [Abstract][Full Text] [Related]
6. Non-steroidal anti-inflammatory drug related upper gastrointestinal bleeding: types of drug use and patient profiles in real clinical practice.
Sostres C; Carrera-Lasfuentes P; Lanas A
Curr Med Res Opin; 2017 Oct; 33(10):1815-1820. PubMed ID: 28569554
[TBL] [Abstract][Full Text] [Related]
7. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.
Mamdani M; Rochon PA; Juurlink DN; Kopp A; Anderson GM; Naglie G; Austin PC; Laupacis A
BMJ; 2002 Sep; 325(7365):624. PubMed ID: 12242172
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of piroxicam-beta-cyclodextrin in the outpatient management of chronic back pain.
Pijak MR; Turcani P; Turcaniova Z; Buran I; Gogolak I; Mihal A; Gazdik F
Bratisl Lek Listy; 2002; 103(12):467-72. PubMed ID: 12696775
[TBL] [Abstract][Full Text] [Related]
9. The Norway study: plasma concentrations, efficacy, and adverse events.
Rugstad HE
Am J Med; 1986 Nov; 81(5B):11-4. PubMed ID: 3538865
[TBL] [Abstract][Full Text] [Related]
10. Piroxicam in recent epidemiologic studies.
Bortnichak EA; Sachs RM
Am J Med; 1986 Nov; 81(5B):44-8. PubMed ID: 3491542
[TBL] [Abstract][Full Text] [Related]
11. [Analgesic efficacy and the tolerance for piroxicam-beta-cyclodextrin compared to piroxicam, paracetamol and placebo in the treatment of postextraction dental pain].
Dolci G; Ripari M; Pacifici L; Umile A
Minerva Stomatol; 1993 May; 42(5):235-41. PubMed ID: 8413108
[TBL] [Abstract][Full Text] [Related]
12. Nature and time-course of piroxicam-induced injury to human gastric mucosa.
Fellows IW; Bhaskar NK; Hawkey CJ
Aliment Pharmacol Ther; 1989 Oct; 3(5):481-8. PubMed ID: 2518861
[TBL] [Abstract][Full Text] [Related]
13. NSAIDs and risk of upper gastrointestinal bleeding.
Henry D; Dobson A; Turner C; Hall P; Forbes C; Patey P
Lancet; 1991 Mar; 337(8743):730. PubMed ID: 1672190
[No Abstract] [Full Text] [Related]
14. Comparison of faecal blood loss, upper gastrointestinal mucosal integrity and symptoms after piroxicam beta-cyclodextrin, piroxicam and placebo administration.
Patoia L; Clausi G; Farroni F; Alberti P; Fugiani P; Bufalino L
Eur J Clin Pharmacol; 1989; 36(6):599-604. PubMed ID: 2673795
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of the restriction in the use piroxicam in Spain.
Maciá Martínez MÁ
Reumatol Clin; 2015; 11(6):345-52. PubMed ID: 25636384
[TBL] [Abstract][Full Text] [Related]
16. Piroxicam concentrations in plasma and synovial fluid after a single dose of piroxicam-beta-cyclodextrin.
Bannwart B; Bertin P; Péhourcq F; Schaeverbeke T; Gillet P; Lefrançois G; Trèves R; Dehais J; Netter P; Gaucher A
Int J Clin Pharmacol Ther; 2001 Jan; 39(1):33-6. PubMed ID: 11204935
[TBL] [Abstract][Full Text] [Related]
17. Piroxicam pharmacokinetics: recent clinical results relating kinetics and plasma levels to age, sex, and adverse effects.
Hobbs DC
Am J Med; 1986 Nov; 81(5B):22-8. PubMed ID: 3538867
[TBL] [Abstract][Full Text] [Related]
18. Effects of piroxicam-beta-cyclodextrin on the gastrointestinal tract.
Warrington S
Eur J Rheumatol Inflamm; 1993; 12(4):29-37. PubMed ID: 7805701
[TBL] [Abstract][Full Text] [Related]
19. Toleration and safety of piroxicam.
Heynen G
Eur J Rheumatol Inflamm; 1987; 8(1):86-93. PubMed ID: 3305037
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.
Olkkola KT; Brunetto AV; Mattila MJ
Clin Pharmacokinet; 1994 Feb; 26(2):107-20. PubMed ID: 8162655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
